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Abstract
IMPORTANCE—Research into the genetic and genomic (“genomics”) foundations of disease
is central to our understanding of disease prevention, early detection, diagnostic accuracy, and
therapeutic intervention. Inequitable participation in genomics research by historically excluded
populations limits the ability to translate genomic knowledge to achieve health equity and ensure
that findings are generalizable to diverse populations.
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OBSERVATIONS—We propose a novel framework for promoting diversity, equity, and inclusion
in genomics research. Building on principles of community-based participatory research and
collective impact frameworks, the framework can guide our understanding of the social, cultural,
health system, policy, community, and individual contexts in which engagement and genomics
research are being done. Our framework highlights the involvement of a multistakeholder
team, including the participants and communities to be engaged, to ensure robust methods
for recruitment, retention, return of genomic results, quality of engagement, follow-up, and
monitoring of participants.
CONCLUSIONS AND RELEVANCE—The proposed engagement framework will guide
investigators in optimizing equitable representation in research and enhancing the rigor of
genomics investigation.

Author Manuscript

Motivation
Germline (inherited) and somatic (eg, tumor) genetic and genomic (“genomic”) technologies
hold great potential to improve health, yet not all individuals and populations benefit equally
from these advances.1 Racially and ethnically minoritized groups participate in research at
much lower rates than majority populations.2 Similarly, minoritized groups make up a small
fraction of cases in genomic databases. Participation in randomized clinical trials does not
reflect population demographics.3, 4

Author Manuscript

Intentional or unintentional exclusion of some populations leads to biased inferences,
genetic misdiagnoses,5, 6 and to clinical practices and care delivery that is insensitive to
or fails to meet the needs of diverse populations. Genomic variation varies by self-identified
race and ethnicity.7 Current reference genomes, a critical component of precision medicine
pipelines, oversample European ancestry. In 1 panassembly of genomes,8 10% of African
DNA sequences were missing from currently used reference genomes. Limited reference
genomes from minoritized populations can lead to elevated rates of variants of uncertain
significance (VUS) that may lead to the misapplication of precision therapies as well as
practices that fail to meet the needs of diverse populations and create or exacerbate health
disparities in historically underserved populations.9, 10
To address the genomic gap in discovery, care, and guidance to institutions and policy
makers, there is a need for theoretically driven approaches for engagement of diverse
JAMA Health Forum. Author manuscript; available in PMC 2022 June 23.
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participants and the communities to which they belong in genomics research. Engagement
in genomics research involves many of the same principles as research in general, but
the addition of genetic and genomic information necessitates addressing information
complexity, culture, preferences, family relationships, individual- and community-level
implications, education regarding the human genome, the role of genomic variations in
disease causation, biospecimen use, data privacy and protections, appropriate data sharing,
and the development of interpretative data narratives that are not unconsciously biased.

Author Manuscript

We propose a framework for participant engagement in genomics research that will facilitate
a mutual partnership between communities and researchers, ensuring that participation in
genomics research will accrue meaningful benefits (and limit harm) to the individual and
community, and promote the development of genomics health policy that is equitable and
inclusive. We have developed this framework to be applied in genomics research. However,
many of the principles and actions presented here have been derived from and can be applied
in biomedical research more generally.

Multistakeholder Structure
Stakeholders include all individuals who should have a voice in the preparation, planning,
and execution of a research project. These groups include content area experts in
study design, laboratory measurement, analysis, and other technical aspects needed to
generate rigorous research results. Community stakeholder participation is required when
the community has an interest in the way research is used, framed, or disseminated.
Stakeholders may also include those who may influence the use of the research results,
including health care professionals at community health centers as well as larger health
systems, departments of health, health systems, policy makers, and payers.
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The stakeholder team should be identified early in defining research goals and plans.
Guidance in the formulation of multistakeholder research is found in Table 1. Researchers
should ask why participants should be drawn from underserved, marginalized, or other
populations; which participants should be considered; how to engage with these participants;
what data and biosamples are needed and how they will be stored; how research results will
be stored, accessed, disseminated, and interpreted to create a data narrative; and how success
will be measured both for researchers and for the community.
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Multistakeholder working groups may provide guidance and recommendations regarding
research priorities and strategies and iteratively reflect on research progress and propose
improvements or address issues that arise during research. Levels of stakeholder engagement
should be defined, including those having roles central to the research vs those serving
in an advisory role. Traditionally, definition of study aims and processes comes from
research and clinical communities. To achieve optimal participation of participants, study
aims and processes should be vetted by the entire stakeholder team. Because genomics
research involves rapidly evolving technical advances and complex ethical, legal, social,
and medical consequences, an effective means of communication across all stakeholders is
critical. This may involve the development of communication tools, presentations, and other
discussion forums so that all stakeholders have a working knowledge and understanding
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relevant to the research. Funding support for all stakeholders should be considered early on
so that appropriate resources are available, and that grant budgets appropriately recognize
the contributions each makes in the research process.
Stakeholders should be made aware of the importance of their input throughout the research
process and be made clearly aware of how this input may shape the development of
future policies by ethics committees, clinical and public health organizations, and payers.
Researchers should provide regular feedback about the positive substantive effect of
stakeholder input.

Framework Values
We propose 4 values for engagement efforts to guide success metrics (Table 2):

Author Manuscript
Author Manuscript

1.

Inclusivity: efforts should be inclusive of a broad population. This involves
convening multistakeholder partners engaged in priority-setting and determining
research conditions consistent with community values and cultural needs. This
value should be maintained across the research continuum from planning through
execution, and in postresearch monitoring and implementation.

2.

Equity: research processes should include diverse perspectives in the
development and implementation of research to achieve optimal diversity in
research participation and translation of research results to clinical and public
health applications. Researchers should limit roadblocks to participation that
might prevent participation by historically underrepresented groups.

3.

Usability: study materials should support a range of health literacy/numeracy
levels, stages in development, and desires for depth of information with language
or cultural linguistic adaptation.

4.

Bidirectionality: study protocols should allow researchers to learn from
participants, and participants to be engaged, empowered, and respected
throughout the process. These values are highly interrelated, and promotion of
each contributes to the fulfillment of the others.

Framework Elements

Author Manuscript

We focus on groups currently underrepresented in genomics research including minoritized
racial/ethnic groups; those living in settings where access to genomic technologies is
limited; and those who are diverse across age groups, sexual identities and gender
orientations, disability, health literacy and numeracy, and those who have intersectional
identities across these groups. The Figure presents a framework around which the inclusion
of diverse participants in research is fundamentally influenced by current and historic
patterns of systemic/structural racism, privilege, and power, as well as political, social, legal,
and other factors that cause specific groups to be disadvantaged. These influences affect the
individual and the communities and institutions with which they interact, and determine an
individual’s interest, willingness, and ability to participate in genomics research or genomic
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clinical diagnostics and genomic-directed therapeutic interventions and clinical trials. The
key elements of our framework are as follows.
Conceptual Foundations

Author Manuscript

Numerous conceptual models have been proposed to optimize participant engagement.11–16
The collective impact framework (CIF)17, 18 provides conditions and metrics to assess
success of participant engagement in research. Community-based participatory research
(CBPR) facilitates collaboration among multisector groups who have common interests
around health and disease.19, 20 We adapt CBPR to genomics research to recognize the
community from which an individual participant is derived as a unit of shared identity;
facilitate bidirectional partnerships in all phases of research; foster colearning and capacity
building among all partners; and achieve a balance between knowledge generation and
health benefit of partner communities. These principles should focus on locally relevant
health problems; appropriately engage participants in review of data and results and
development of the data narrative; commit to sustainability; address issues of race, ethnicity,
racism, and social class; embody cultural humility; and ensure research rigor and validity.
Context
Multilevel contextual factors that affect participant engagement in genomics research
include individual, social, and health system influences on human health and disease. We
draw from the theory of reasoned action18 to consider:

Author Manuscript
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•

Cognitive issues: information processing, health literacy, ability to comprehend
complex research/clinical proposals, knowledge of genetics/genomics and its use
or value in their life or health care choices and decision-making.

•

Attitudes and beliefs: preferences, fear, or patient experiences that contribute
to willingness for research participation; trauma or stigma; individual genetic
privacy and confidentiality; religious or cultural concerns regarding collection of
biospecimens and their future use; and privacy and use of genomic results.

•

Social and structural: social and community context, particularly in cultures for
which community support or approval of decision-making influences individual
decision-making, such as in American Indian communities. Socioeconomic
position affects access to genomics research or services owing to cost or
insurance barriers.

•

Subjective norms and motivation to comply: physical access may be limited
by individual needs including childcare, eldercare, time off from work,
transportation. Cultural perspectives and beliefs of family or friends and other
support networks including culturally based concerns such as ethnic or tribal
identity or individual genetic privacy.

•

Health system: health system context involves institutions with which research
participants interact. Institutions may prioritize profit over service to diverse
populations intentionally, unintentionally, or because of limited resources
or infrastructure. They may provide limited accommodation in services or
staff training to meet the needs of diverse participants and communities
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they serve, or for their staff to be appropriately acculturated and trained in
unconscious bias to accommodate language, culture, or preferences for informed
consent, questionnaires, unnecessary exclusions or eligibility and participation
requirements that disproportionately affect certain groups. Researchers may not
take steps to present the study and garner buy-in from community leaders or
other family or social, cultural, or religious networks that reach beyond the
individual’s consent to participate in research. Limiting which insurance plans
are accepted by the institution may bar some groups from accessing genomics
research and services.
Participant-Centeredness
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Participant-centeredness is key to ensure optimal effect of research findings.21 Research
consent should explicitly explain that anonymized, deidentified data will be deposited into
public databases. Participant-centered questions should be anticipated and included in study
materials. For example:
•

What are my options for receiving genetic information if I participate in
research?

•

What should I expect with regard to my health?

•

What will happen to the biosample I provide for testing and analysis?

•

How can my genomic data help others?

•

Who will have access to my genomic data and how will they be used?

•

How are my identity and privacy protected?

Author Manuscript

Recruitment
Population-based recruitment strategies can exclude subgroups that are difficult to reach or
participate at lower rates. Newer approaches to cohort-based research such as All of Us,22
Count Me In,23 and MindCrowd24 use internet-based platforms to engage participants who
can enroll and participate in genomics-focused research remotely. Concerns about these
approaches have been raised by some communities.25 Virtual approaches are dependent
on participants and communities having adequate internet access, which is challenging for
many rural, underserved, and indigenous communities.
Retention

Author Manuscript

Realistic assessment of the feasibility and acceptability of research requirements is critical
to avoid participation attrition. Literacy, numeracy, and multiple (in-person) visits represent
retention barriers. Supports and structures that participants require to remain engaged could
include use of telehealth and remote communication and consenting options, minimization
of the need and time and cost of travel to a study center or support for travel and
engagement costs, or community-based discussions responsive to community preferences.
An understanding of attrition for genomic protocols in specific populations will lend itself
to a stepwise, targeted approach to improve retention and maximize opportunities for
participation in genomics research.
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Engagement quality depends on the development and maintenance of appropriate and
tailored strategies that lead to the “meaningful involvement of patients, caregivers,
clinicians, and other healthcare stakeholders throughout the entire research process
and beyond.”11 Engagement requires relationships and trust between the researchers
and participants from concept, development, execution, monitoring, dissemination, and
implementation. Development of a nonbiased data narrative, translation of the research
both to the individual participant and their community, and assessment of its individual,
community, and societal effect are required.
Return of Genomic Results (ROGR)
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Knowledge that facilitates ROGR is increasingly available,26–30 although standard processes
for ROGR in diverse groups are challenged by rapid changes in technology and knowledge.
The observation that Black, Asian, and Hispanic women are more likely to undergo
genetic testing for therapeutic purposes (ie, after a diagnosis) than for risk assessment and
management has informed participant and clinician issues in ROGR.31 Uncertainty about
clinical actionability32–35 exists regarding somatic (tumor) ROGR, whether it be to the
research participant or their clinician.36 This is particularly true in understudied populations
where reference genomes have not been developed and VUS may be common. Efforts to aid
participants to understand genomic results can involve genetic counselors and other trained
personnel,36, 37 who are limited in supply and may not have training to manage the needs of
minoritized groups. Even less is known about how best to present results to populations with
lower levels of health literacy, the culturally diverse, non–English speaking, or adolescent
participants.38 Educational materials adapted to specific populations require tailoring around
culture, beliefs, language, educational level, and other factors. Educational materials should
also consider each community’s individual or collective cultural context and explain how
participation in genomics research will contribute to personal health and improve care for
other members of the participant’s community.
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Monitoring
Participants who receive genomic results may require recontact if new clinically relevant
and actionable findings are discovered that may affect clinical management or care. This is
particularly likely where genomic sequencing is more likely to reveal VUS at the time of
testing. It is critical that relationships with the participant be maintained throughout their
study participation to ensure recontact is welcomed by and beneficial to the participant.
Implementation

Author Manuscript

Although the concepts presented in the framework will in theory improve diversity in
genomics research participation, there are substantial barriers to their implementation.
Historically, it has been difficult to obtain the funding required to undertake the laborand time-intensive processes required to achieve this goal. Often, funders do not pay
for the development of these processes, particularly because these activities may require
long-term commitments and engagement with the community that involve ongoing costs
(well beyond the usual NIH 5-year grant cycle). The lag between building community
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engagement in research and downstream availability of diverse biosamples and data are a
further barrier. This is exacerbated by the fundamental disconnect between the rapid pace
of genomics research, which often involves quick discovery and turnaround of reporting,
and the slow and continuous processes needed to establish community linkages. Currently,
there are limited academic incentives for many in the genomics community to engage
with communities. A partnership model between genomicists and community-engaged
researchers and institutional community liaisons may be considered to achieve diversity
goals. Given recent attention to the importance of diversity in addressing major health
problems suggests opportunities for funding and other resources to address these issues may
be forthcoming.

Phased Process
Author Manuscript

Our framework (Table 3) involves phases defined by the CBPR and CIF
models12, 13, 16, 19, 20 that include generation of ideas and dialogue, initiating action,
organizing for effect, and sustaining actions and effect for each activity.
Phase 1: Define Context

Author Manuscript

Prior to research initiation, the knowledge landscape that guides research questions and
actions should be explored and understood. The team should understand the historical,
social, cultural, community, and economic factors that influence engagement (or lack
thereof) in genomics research. The contextual background may be specific to each research
question as well as the populations in which the data may be translated. Preresearch
considerations include asset identification, local values, data gathering approaches,
the policy-making process, visual and social media, and scale of future policy and
implementation.20
The state of knowledge about genomic variation, population and evolutionary genetics, and
biomarker distributions should be understood for the population under study. Practice gaps
including access to sophisticated genomic technologies that may be unavailable to some
relevant groups in future clinical practice should be understood. Continuous monitoring
and updates of these settings should be undertaken in response to new data, knowledge, or
conditions.39
Phase 2: Establish Partnership Processes and Governance

Author Manuscript

The research team should engage with cross-sector stakeholders, community advisory
boards, laboratories, advocates, researchers, policy makers, ethicists, health care
professionals, and others. Focus groups representative of future research participants
and other stakeholders should be undertaken to understand the state of knowledge and
community needs and preferences. Diverse cross-sector teams should identify stakeholder
resources, social capital, shared values, and time commitments. Researchers should identify
opportunities to execute and implement the research by understanding the cultural and
linguistic setting. This process should result in a common agenda, goals, and strategy for
the research. It should build stakeholder trust, plan for conflict management, and identify
leadership in specific research domains.
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Phase 3: Prepare for Research
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By now, research goals, needs, gaps, and processes should have been discussed
among all stakeholders. Stakeholder input should identify participant issues and future
community implementation related to generation of genomic data; genomic data privacy
and confidentiality; ethical, legal, social, and family issues; cost and insurance; data
interpretation and use; data sharing; biosample storage, future use, and return; implications
on current and future health and health care; and implications for treatment and monitoring
for those who may currently be participants or who are at risk of developing a condition
related to the genomic data.
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Research protocols should consider stakeholder needs to motivate culturally appropriate
shared surveys, metrics, indicators, and measurements. Biosample collection or laboratory
assays can be adapted to the population under study at this time, and perhaps earlier
if pilot testing of biosampling methods, collection, processing, or storage are required.
Development and implementation of protocols for genomic data curation, communication,
and storage must be consistent with the legal requirements, needs, goals, and preferences
of the communities under study. Considerations for future data sharing, access, and risks of
reidentification must be delineated. Because the knowledge and translation of genomic data
changes rapidly, consideration for potential use of the data for purposes other than originally
intended, including unpredictable future clinical actionability, must be stated.

Author Manuscript

In engaging stakeholders who are directly affected by disease, realistic and feasible
responsibilities of research participants should also be defined. The psychosocial, economic,
and personal burdens of disease to the participant and their caregivers are not trivial,
and may impose burdens that are not clear to the researcher who does not have a good
understanding of the participant-centered setting.
Culturally appropriate shared metrics, indicators, and measurements should be developed
and applied by study staff that understand the context and community conditions where
the study is being done. Unnecessary exclusion criteria that limit the participation of some
groups can be understood and eliminated such as requirements to speak English or have
no comorbidities. These exclusions not only excessively disadvantage some populations
from participating in research, but also restrict the generalizability of future applications of
the intervention. Expert guidance from knowledgeable oversight bodies (eg, clinical trials
offices, IRBs) that minimize undue barriers from research participation should be sought.

Author Manuscript

Protocols should be developed to ensure optimal ROGR, particularly if these results have
health or social implications to the participant and their relatives. The ROGR should assume
participants may fall across a range of health literacy levels, ages, beliefs, and stages in
development. Achieving this goal requires early consultation with stakeholders who can
confirm that if ROGR is planned, communication is beneficent, causes no harm, can be
acted on, and downstream health issues are clear to the participant, and possibly to their
community. Potential for recontact should be developed in light of new clinically relevant or
actionable information becoming available.
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Much of the activity required to undertake genomics research in diverse populations occurs
well before the first participant is recruited. Continued dialogue with all stakeholders
including formal (eg, advisory board meetings) and informal communication should occur
regularly so that adaptations can be made to the protocols based on knowledge gained as
the research is being undertaken. As in a clinical trial, a stakeholder advisory board can
monitor adverse events (eg, miscommunications, improper information flow, unfavorable
participant or community reactions to the research) and suggest remedies. A system for
ongoing monitoring and reporting of research progress should be in place so that a rapid
response can be mounted when new situations or adverse events arise.
Phase 5: Implement Findings and Inform Health Policy

Author Manuscript

Ongoing monitoring and evaluation of the research process, including diversity of enrolled
population and participant attrition, will allow remediation of research in process and
provide context around which research results can be interpreted and implemented. Ongoing
assessment of clinical and policy effects, partnership viability, and shared goals is also
required. An understanding of unintended events, barriers to participation, accrual, and
retention will inform the potential effect of the research for translation to the stakeholder
groups (eg, health care settings, communities) in which the results may be applied.
As research results become available and focused development of implementation or
dissemination of research data are possible, stakeholders should assess readiness for
change of the clinical, patient, population or others who may use the intervention.39 An
understanding of reasons for low participation, high attrition, or inadequate communication
of results identified during the research process may inform future implementation. This
information will also inform resource needs that can be applied or extended to disseminate
research data to communities and identify change mediators and behaviors that will ensure
genomic information can be broadly disseminated to diverse populations. Use of wellestablished implementation metrics, such as the Reach-Efficacy-Adoption-ImplementationMaintenance (RE-AIM) framework,40 will maximize future implementation of evidencebased approaches into standard practices and processes. These practices and processes can
inform the establishment of health policy for genomics research that are both scientifically
robust and responsive to the unique experiences of diverse participants.

Author Manuscript
Limitations

The practices and processes described herein will require further theoretical and empirical
research to refine and optimize effects.

Author Manuscript

Conclusions
The participation of historically marginalized, underserved, and understudied groups in
genomics research has limited progress in understanding human disease genomics, and has
been a barrier to addressing health disparities. The framework is developed without respect
to a specific disease or clinical application, but we acknowledge that adaptations may be
required to apply these concepts for specific diseases to accommodate biological, clinical,
or treatment issues. For example, somatic genomics will be highly relevant to cancer, but
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much less relevant to cardiovascular disease where germline genomics may predominate.
The framework proposed here can guide research teams to improve their ability to engage
traditionally understudied populations by guiding the planning and execution of genomics
research to have maximal clinical, public health, and policy effects.
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Table 1.

Author Manuscript

Considerations During Preparation for Genomics Studies Involving Participants Typically Underrepresented in
Research
Domain
Sample design

Communication

Process

Author Manuscript
Author Manuscript

Outputs

Questions to be considered
•

Are diverse populations needed to achieve the research objectives? If so, why?

•

What diverse groups should be included to address the scientific question of interest?

•

What sample size and statistical power are required to answer research questions and maximize the potential
for generalizability in population subgroups (eg, analyses by race or ethnicity)?

•

How should bidirectional relationships with participant, community, advocacy, and other partners be
developed and managed to ensure appropriate community input for research design, execution, use and
reporting of data, communication back to the community?

•

How will participant accrual, retention, and ongoing follow-up be collected, tracked, reported, and evaluated?

•

How will the biospecimens be collected, used (current and future), stored, returned, disposed? How can
biospecimens be withdrawn? Need for active consent for secondary use or future use of biospecimens? How
can tribal, traditional, and religious or spiritual leaders participate in defining processes for biospecimen
handling?

•

What are measures of optimal engagement (ie, empowerment, trust, respect, such as respect for sovereignty of
tribal and other nations)?

•

What informed consent, confidentiality, and other elements of human participants research need to be
considered and how? Should these be culturally, linguistically, literacy, or otherwise tailored to the populations
being studied? How can participants opt out now or in the future?

•

What authorities or institutional and/or community review boards, beyond that of the traditional health system
institutional review board (IRB), such as tribal IRBs and community IRBs be engaged in protocol and consent
review?

•

What data use and data sharing agreements need to be considered? How can sovereign Tribal Nations and
other communities participate in developing these shared agreements?

•

What baseline data and biosamples are required? How will these be stored and accessed? How will future use
and participant recontact be defined?

•

What common data collection instruments, interviews, and surveys should be available? Can these be
standardized for common collection across studies and centers that may increase future data sharing?

•

Can data or samples be deidentified, or is participant recontact required, and if so, how will this be
accomplished?

•

Are shared decision-making or other models appropriate for community engagement throughout the research
process?

•

What success measures and metrics are required to maximize participant experiences, empowerment, and
self-advocacy?

•

How will return of genetic or genomics results be managed?

•

What means of communicating ongoing participation, results reporting, and translation of findings back to the
community should be undertaken?

•

What genomic findings will be reported back to the participants, and how?

•

What unintended consequences of research participation or receiving information might arise in genomics
studies?
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Table 2.

Author Manuscript

Framework Values and Success Metrics
Value

Processes and feedback

Potential success metrics

Inclusivity

•

Participant reports of acceptability of
recruitment materials and interfaces.

•

Representativeness of enrollment and retention for full
sample and subpopulations relative to population of
inference.

Equity

•

Participant identification of
roadblocks in recruitment and
retention process.

•

Enrollment and retention rates (overall and at
each step from consent through recontact, as
appropriate) reflect the diversity of the full sample and
subpopulations of interest.

•

Ability to generalize and translate research results to
diverse populations.

•

Rates of return of genomic results.

•

Time to return of genomic results.

Usability

Author Manuscript

Bidirectionality

•

Participant and study staff feedback
on materials and reports, including
format, content, and how information
is shared.

•

Participation in feedback surveys and
interviews.

•

Participation in initiatives focused on
underserved populations.

•

Engagement of partners.

•

Efficiency of uptake of findings
to standard processes (time from
conclusion of pilot to incorporation).

•

Uptake rates of genetic counseling.

•

Participant understanding of findings.

•

Participant understanding of clinical implications of
results.

•

Effect on participants (participant empowerment,
feeling respected and valued, willingness to continue
engagement).

•

Time from conclusion of pilot work to incorporation
into standard processes.
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Table 3.

Author Manuscript

A Framework for Engagement of Diverse Participants in Genetics and Genomics Research
Community-based
participatory
research
dimension
Phase 1: define
context

Author Manuscript

Phase 2: establish
partnership
processes and
governance

Phase 3: prepare for
research

Author Manuscript
Phase 4: conduct
research

Author Manuscript

Phase 5: implement
findings and inform
health policy

Collective impact
dimension
Sustain action and
impact

Ideas and dialogue

Initiate action

Organize for impact

Map the current landscape:
social, structural, policy,
health care, capacity,
readiness, and other factors
relevant to the stakeholders’
participation in genomics
research.

Monitor and refine context
in response to new data,
knowledge, or conditions.

Monitor and refine context
to response to new data,
knowledge, or conditions.

Monitor and refine
context to response to
new data, knowledge,
or conditions.

Common agenda

Continuous communication

Continuous communication

Continuous
communication

Identify and hold
dialogue with crosssector stakeholders and
champions, including
laboratories, clinical service
professionals, community
members, researchers,
policy makers, ethicists,
and others.

Form diverse cross-sector
teams. Assess need for
agreements, resources, social
capital, shared values, and
time commitments. Ensure
research teams include staff
who can implement proposed
research using culturally
and linguistically tailored
methods.

Create a common
agenda, goals, and
strategy. Facilitate
stakeholder outreach, build
stakeholder trust, conflict
management, leadership,
decision-making.

Monitor and refine
context to response to
new data, knowledge,
or conditions.

Mutually reinforcing
activities

Backbone support

Backbone support

Continuous
communication

Convene stakeholder
dialogue to identify issues:
genomic data, privacy,
trust, data use, ethical,
legal, family issues,
insurance, current and
future health and health
care, implications for
treatment and monitoring,
and others. Determine
stakeholder needs and
requirements for moving
forward with research.
Possibly conduct a
community health needs
assessment.

Summarize baseline data to
motivate planned research
and identify key gaps
and issues likely to arise.
Involve stakeholders to
develop culturally appropriate
shared metrics, indicators,
measurements, approaches.
Create molecular panels or
methods that adequately
capture diverse genomic
variation by (eg) race
and ethnicity. Develop and
implement protocols for
genomic data curation,
communication, and return
of results. Create culturally
tailored educational tools for
research participants.

Create partnership
infrastructure that
incorporates stakeholder
knowledge, empowering
processes. Create
stakeholdercentered
interventions, research
tools, and study designs.

Monitor and refine
context to response to
new data, knowledge,
or conditions.

Mutually reinforcing
activities

Shared measurement

Mutually reinforcing
activities

Continuous
communication

Record and re-evaluate
dialogue on an ongoing
basis as research proceeds.

Utilize culturally appropriate
shared metrics, indicators,
measurements, approaches.
Streamline clinical trials
processes, limit unnecessarily
restrictive study exclusion
criteria.

Regular bidirectional
interactions across
stakeholders to monitor
research progress, arising
issues, and impact

Collect, track, and
report on research
progress, including
unintended events.

Continuous communication

Shared measurement

Continuous communication

Continuous
communication

Record and re-evaluate
dialogue on an ongoing
basis as research proceeds.

Record and re-evaluate
dialogue on an ongoing basis
as research proceeds.

Establish predefined
metrics of success.
Identify, communicate, and
remediate issues arising
during research.

Assess clinical
and policy impact,
partnership viability,
shared goals,
cultural reinforcement.
Research productivity
and impact on focus
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Collective impact
dimension
Ideas and dialogue

Initiate action

Organize for impact

Sustain action and
impact
stakeholder groups.
Reassess process in
light of unintended
events or new
knowledge gained.

Continuous communication

Continuous communication

Shared measurement
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Author Manuscript
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